How the IRA makes new small molecule biotech R&D uninvestable for diseases of aging

Presentations
Written By Ryan Crane

By price setting small molecule medicines after only 9 years on the market, the Inflation Reduction Act threatens investments in future cures. The law’s disparate treatment of small and large molecules will warp R&D and result in fewer new cures, particularly those for cancer and other diseases of aging.

Ryan Crane
Previous

The Harmful Consequences of the US Adopting the UK’s Math for Setting Drug Prices
Next

The Investor’s Paradox